A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Trial Details

NCT ID

NCT06907615

Phase

PHASE2

Sponsor

Shanghai Henlius Biotech

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• HLX43 DOSE 1 (2.0 mg/kg)
• HLX43 DOSE 2 (2.5 mg/kg)

Locations (sample)

• Houston, Texas, United States|29.76328,-95.36327
• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• Have a full understanding of the study content, process, and possible adverse reactions before the study, and sign the informed consent form (ICF);…
• Aged ≥ 18 years at the time of signing the ICF, male or female;
• Histologically or cytologically confirmed, locally advanced (stage IIIB/IIIC) or metastatic (stage IV) NSCLC not suitable for radical treatment (co…
• Subjects without actionable genomic alterations (AGAs):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.